Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chiara Cremolini

Showing results (121-130 of 284) with videos related to

Pageof 29
Sort By:
ESMO Open|December 7, 2017
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical studyChiara Cremolini, Filippo Pietrantonio, Gianluca Tomasello, et al.
Scientific Reports|April 26, 2020
Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
Clinical Colorectal Cancer|April 12, 2018
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) StudyDiana L Hanna, Fotios Loupakis, Dongyun Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2009
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerFotios Loupakis, Luca Pollina, Irene Stasi, et al.
BMC Cancer|June 15, 2011
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancerFotios Loupakis, Annamaria Ruzzo, Lisa Salvatore, et al.
The Pharmacogenomics Journal|January 29, 2019
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenibMarta Schirripa, Beatrice Borelli, Romina D'Aurizio, et al.
ESMO Open|June 25, 2019
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectableElena Ongaro, Chiara Cremolini, Daniele Rossini, et al.
Clinical Colorectal Cancer|August 25, 2021
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD StudyEleonora Lai, Marco Puzzoni, Pina Ziranu, et al.
JCO Clinical Cancer Informatics|July 17, 2024
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal CancerMarinde J G Bond, Maarten van Smeden, Koen Degeling, et al.
BMC Cancer|January 27, 2018
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patientsFrancesca Battaglin, Marta Schirripa, Federica Buggin, et al.
Pageof 29

Showing results (121-130 of 284) with videos related to

Sort By:
Pageof 29
ESMO Open|December 7, 2017
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical studyChiara Cremolini, Filippo Pietrantonio, Gianluca Tomasello, et al.
Scientific Reports|April 26, 2020
Author Correction: The landscape of d16HER2 splice variant expression across HER2-positive cancersChiara Costanza Volpi, Filippo Pietrantonio, Annunziata Gloghini, et al.
Clinical Colorectal Cancer|April 12, 2018
Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) StudyDiana L Hanna, Fotios Loupakis, Dongyun Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2009
PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancerFotios Loupakis, Luca Pollina, Irene Stasi, et al.
BMC Cancer|June 15, 2011
Retrospective exploratory analysis of VEGF polymorphisms in the prediction of benefit from first-line FOLFIRI plus bevacizumab in metastatic colorectal cancerFotios Loupakis, Annamaria Ruzzo, Lisa Salvatore, et al.
The Pharmacogenomics Journal|January 29, 2019
Early modifications of circulating microRNAs levels in metastatic colorectal cancer patients treated with regorafenibMarta Schirripa, Beatrice Borelli, Romina D'Aurizio, et al.
ESMO Open|June 25, 2019
Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectableElena Ongaro, Chiara Cremolini, Daniele Rossini, et al.
Clinical Colorectal Cancer|August 25, 2021
Long Term Survival With Regorafenib: REALITY (Real Life in Italy) Trial - A GISCAD StudyEleonora Lai, Marco Puzzoni, Pina Ziranu, et al.
JCO Clinical Cancer Informatics|July 17, 2024
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal CancerMarinde J G Bond, Maarten van Smeden, Koen Degeling, et al.
BMC Cancer|January 27, 2018
The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patientsFrancesca Battaglin, Marta Schirripa, Federica Buggin, et al.
Pageof 29